Melola Discovery

← Melola Discovery

Jurnal Tanpa peringkat SINTA

THE COMPARISON OF EFFECTIVENESS AND SAFETY BETWEEN WARFARIN AND RIVAROXABAN IN HYPERCOAGULATED CENTRAL NERVOUS SYSTEM TUMORS

Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan · Vol. 11 No. 1 (2023) · hlm. 88–99

DOI
10.22437/jmj.v11i1.25056
ISSN
2580-6874, 2339-269X
Terbit
2023-06-02
Penerbit
FAKULTAS KEDOKTERAN DAN ILMU KESEHATAN UNIVERSITAS JAMBI
Bahasa
en

Abstrak

Abstract:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Background: Central nervous system (CNS) tumors originate from the brain and spinal cord, and have complications, such as hypercoagulation. The administration of anticoagulants (warfarin and rivaroxaban) has been able to reduce hypercoagulation-related morbidity and mortality, however, the effectiveness and safety of their use has not been well studied. This study aims to compare the effectiveness and safety of anticoagulant drugs between warfarin and rivaroxaban in hypercoagulated CNS tumors. Methods: This was a randomized clinical trial study, double-blinded, conducted on CNS tumor patients from September-November 2020 at Mohammad Hoesin Hospital. The patients were given warfarin and rivaroxaban for 3 weeks. Coagulation status was measured before and after. Data were analyzed using SPSS ver.24. Results: The mean age of 20 patients was 42.70+8.14 years and majority were female (80%), with tumor characteristics were primary (80%), single (85%), and located in the brain (95%). In the warfarin group (n=10), there were significant improvements in PT (p 0.008), INR (p 0.013), Fibrinogen (p 0.041), and D-Dimer (p 0.008) value, also the rivaroxaban group (n=10) in PT (p 0.013), APTT (p 0.012), INR (p 0.028), Fibrinogen (p 0.047), D-Dimer (p 0.032), and Anti Fxa (p 0.028). However, there was no significant difference between groups, except when comparing the Anti Fxa delta (p 0.041). There was 1 person with major bleeding using warfarin, and 1 person (excluded) with GIT bleeding using rivaroxaban. Conclusion: There was a significant improvement of coagulation value in both groups, also side effects were seen as well. Keyword: CNS Tumor, Hypercoagulation, Warfarin, Rivaroxaban

Jaringan kolaborasi para penulis

4 penulis · 6 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://online-journal.unja.ac.id/index.php/kedokteran/oai, pertama di-harvest 6 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">THE COMPARISON OF EFFECTIVENESS AND SAFETY BETWEEN WARFARIN AND RIVAROXABAN IN HYPERCOAGULATED CENTRAL NERVOUS SYSTEM TUMORS</dc:title>
	<dc:creator xml:lang="en">Yusuf, Sri noviyanty</dc:creator>
	<dc:creator xml:lang="en">Yunni Diansari </dc:creator>
	<dc:creator xml:lang="en">Mediarty Syahrir</dc:creator>
	<dc:creator xml:lang="en">Phey Liana</dc:creator>
	<dc:description xml:lang="en">Abstract:                                                                                                                                           
Background: Central nervous system (CNS) tumors originate from the brain and spinal cord, and have complications, such as hypercoagulation. The administration of anticoagulants (warfarin and rivaroxaban) has been able to reduce hypercoagulation-related morbidity and mortality, however, the effectiveness and safety of their use has not been well studied. This study aims to compare the effectiveness and safety of anticoagulant drugs between warfarin and rivaroxaban in hypercoagulated CNS tumors.
Methods: This was a randomized clinical trial study, double-blinded, conducted on CNS tumor patients from September-November 2020 at Mohammad Hoesin Hospital. The patients were given warfarin and rivaroxaban for 3 weeks. Coagulation status was measured before and after. Data were analyzed using SPSS ver.24.
Results: The mean age of 20 patients was 42.70+8.14 years and majority were female (80%), with tumor characteristics were primary (80%), single (85%), and located in the brain (95%). In the warfarin group (n=10), there were significant improvements in PT (p 0.008), INR (p 0.013), Fibrinogen (p 0.041), and D-Dimer (p 0.008) value, also the rivaroxaban group (n=10) in PT (p 0.013), APTT (p 0.012), INR (p 0.028), Fibrinogen (p 0.047), D-Dimer (p 0.032), and Anti Fxa (p 0.028). However, there was no significant difference between groups, except when comparing the Anti Fxa delta (p 0.041). There was 1 person with major bleeding using warfarin, and 1 person (excluded) with GIT bleeding using rivaroxaban.
Conclusion: There was a significant improvement of coagulation value in both groups, also side effects were seen as well.
Keyword: CNS Tumor, Hypercoagulation, Warfarin, Rivaroxaban</dc:description>
	<dc:publisher xml:lang="en">FAKULTAS KEDOKTERAN DAN ILMU KESEHATAN UNIVERSITAS JAMBI</dc:publisher>
	<dc:date>2023-06-02</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://online-journal.unja.ac.id/kedokteran/article/view/25056</dc:identifier>
	<dc:identifier>10.22437/jmj.v11i1.25056</dc:identifier>
	<dc:source xml:lang="en">Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan; Vol. 11 No. 1 (2023): Jambi Medical Journal: Jurnal Kedokteran dan Kesehatan ; 88-99</dc:source>
	<dc:source>2580-6874</dc:source>
	<dc:source>2339-269X</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://online-journal.unja.ac.id/kedokteran/article/view/25056/15612</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2023 JAMBI MEDICAL JOURNAL "Jurnal Kedokteran dan Kesehatan"</dc:rights>
</oai_dc:dc>